Latest news and press releases about Precision BioSciences, Inc. (DTIL): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases.
Price
| Price | $6.63 |
| Market Cap | $85M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.78 |
| EV / EBITDA | -0.76 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -91.60% |
| Return on Invested Capital | -30.23% |
| Return on Assets | -41.88% |
| Gross Margin | 100.00% |
| Operating Margin | -80.78% |
| Net Margin | -117.04% |
Related companies: ABOS · ALEC · GOSS · HOOK · HRTX · KLDO · QTTB
Explore sector: Healthcare · Biotechnology
More sections of DTIL: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks